FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014805265> ?p ?o ?g. }

• W2014805265 abstract "Despite large improvements in cardiovascular disease mortality, coronary heart disease (CHD) and stroke remain the leading causes of death in most nations around the world [1,101]. Statins are the foundation for cardiovascular prevention, with up to 50% reductions in cardiovascular risk with the more potent statins [2]. In both statin-treated and -untreated patients, low levels of high-density lipoprotein cholesterol (HDL-C) are an important predictor of subsequent cardiovascular risk [3,4]. In epidemiologic studies, each 1 mg/dl (0.03 mmol, or ~2–3%, depending on baseline HDL-C level) increase in HDL-C is associated with a 2–4% reduction in the risk of CHD events, independent of low-density lipoprotein cholesterol (LDL-C) levels [5]. Of the drugs currently on the market, niacin is the most effective at raising HDL-C (~25% at the 2-g dose), while statins and fibrates have more modest HDL-C-raising effects (3–10%) [6]. However, it is not clear that pharmacologically raising HDL-C per se with these agents reduces cardiovascular risk. A meta-ana lysis of HDL-C-raising drugs found that after adjusting for LDL-C-lowering, raising HDL-C (or lowering triglycerides) was not associated with further cardiovascular risk reduction [6]. Several classes of HDL-C-raising agents with novel mechanisms of action are under development [7]. Farthest along are the cholesteryl ester transfer protein (CETP) inhibitors. CETP mediates the transfer of cholesteryl esters from HDL to proatherogenic apolipoprotein B-lipoproteins for transportation of cholesterol back to the cells; blocking CETP increases levels of mature HDL-C particles. The first CETP inhibitor to move into clinical trials was torcetrapib (Pfizer, Inc). Despite large increases in HDL-C, development of torcetrapib was terminated due to excess mortality in the torcetrapib group of the large outcomes trial, Investigation of Lipid Level management to Understand its Impact in Atherosclerotic Events (ILLUMINATE). Increased mortality in the torcetrapib-treated group occurred despite a 72% increase in HDL-C and a 25% decrease in LDL-C [8]. Torcetrapib also had no benefit on atherosclerotic progression in two noninvasive imaging studies, despite similar lipid changes [9,10]. The adverse mortality effect of torcetrapib has been largely attributed to accelerated hypertension due to activation of the renin–angiotensin–aldosterone system through a non-CETP-dependent effect [11]. Other mechanisms, such as lack of HDL functionality and proinflammatory effects, have also been proposed to explain torcetrapib’s adverse effects. Two CETP inhibitors are still in development, anacetrapib and dalcetrapib. Neither agent has been found to increase blood pressure or influence the renin– angiotensin–aldosterone axis in studies to date [7]. The more potent CETP inhibitor, anacetrapib, comes from the same chemical class as torcetrapib and strongly binds to the CETP molecule. Added to optimal statin therapy, anacetrapib 100 mg has been shown to increase HDL-C by 138% and reduce LDL-C an additional 40%, with modest triglyceride-lowering effects [12]. The less potent dalcetrapib is from a different chemical class, binds reversibly to and induces a different conformational “Given the excess mortality caused by torcetrapib, it is unlikely that any CETP inhibitor will receive regulatory approval prior to the completion of the long-term cardiovascular end point trials...”" @default.
• W2014805265 created "2016-06-24" @default.
• W2014805265 creator A5089418361 @default.
• W2014805265 date "2011-03-01" @default.
• W2014805265 modified "2023-09-25" @default.
• W2014805265 title "Is there a future for CETP-inhibitor therapy?" @default.
• W2014805265 cites W1970516435 @default.
• W2014805265 cites W1972513668 @default.
• W2014805265 cites W1973355122 @default.
• W2014805265 cites W2003671495 @default.
• W2014805265 cites W2014558113 @default.
• W2014805265 cites W2048760408 @default.
• W2014805265 cites W2058536244 @default.
• W2014805265 cites W2064366700 @default.
• W2014805265 cites W2077760013 @default.
• W2014805265 cites W2090464684 @default.
• W2014805265 cites W2105346195 @default.
• W2014805265 cites W2108475045 @default.
• W2014805265 cites W2117622925 @default.
• W2014805265 cites W2135020991 @default.
• W2014805265 cites W2135459459 @default.
• W2014805265 cites W2138590740 @default.
• W2014805265 cites W2139168645 @default.
• W2014805265 cites W2141210634 @default.
• W2014805265 cites W2144739178 @default.
• W2014805265 cites W2152683287 @default.
• W2014805265 cites W2156281737 @default.
• W2014805265 cites W2158057499 @default.
• W2014805265 cites W2164089346 @default.
• W2014805265 cites W2164324917 @default.
• W2014805265 cites W2413706018 @default.
• W2014805265 cites W2477872031 @default.
• W2014805265 cites W818906334 @default.
• W2014805265 doi "https://doi.org/10.4155/cli.11.10" @default.
• W2014805265 hasPublicationYear "2011" @default.
• W2014805265 type Work @default.
• W2014805265 sameAs 2014805265 @default.
• W2014805265 citedByCount "0" @default.
• W2014805265 crossrefType "journal-article" @default.
• W2014805265 hasAuthorship W2014805265A5089418361 @default.
• W2014805265 hasConcept C126322002 @default.
• W2014805265 hasConcept C134018914 @default.
• W2014805265 hasConcept C2776839432 @default.
• W2014805265 hasConcept C2778163477 @default.
• W2014805265 hasConcept C2780072125 @default.
• W2014805265 hasConcept C2780092750 @default.
• W2014805265 hasConcept C45505151 @default.
• W2014805265 hasConcept C62746215 @default.
• W2014805265 hasConcept C71924100 @default.
• W2014805265 hasConcept C98274493 @default.
• W2014805265 hasConceptScore W2014805265C126322002 @default.
• W2014805265 hasConceptScore W2014805265C134018914 @default.
• W2014805265 hasConceptScore W2014805265C2776839432 @default.
• W2014805265 hasConceptScore W2014805265C2778163477 @default.
• W2014805265 hasConceptScore W2014805265C2780072125 @default.
• W2014805265 hasConceptScore W2014805265C2780092750 @default.
• W2014805265 hasConceptScore W2014805265C45505151 @default.
• W2014805265 hasConceptScore W2014805265C62746215 @default.
• W2014805265 hasConceptScore W2014805265C71924100 @default.
• W2014805265 hasConceptScore W2014805265C98274493 @default.
• W2014805265 hasLocation W20148052651 @default.
• W2014805265 hasOpenAccess W2014805265 @default.
• W2014805265 hasPrimaryLocation W20148052651 @default.
• W2014805265 hasRelatedWork W16579762 @default.
• W2014805265 hasRelatedWork W1970111553 @default.
• W2014805265 hasRelatedWork W1985322784 @default.
• W2014805265 hasRelatedWork W2002194333 @default.
• W2014805265 hasRelatedWork W2009220054 @default.
• W2014805265 hasRelatedWork W2081327475 @default.
• W2014805265 hasRelatedWork W2083507558 @default.
• W2014805265 hasRelatedWork W2089967736 @default.
• W2014805265 hasRelatedWork W2105346195 @default.
• W2014805265 hasRelatedWork W2108594199 @default.
• W2014805265 hasRelatedWork W2114641531 @default.
• W2014805265 hasRelatedWork W2124503642 @default.
• W2014805265 hasRelatedWork W2127608622 @default.
• W2014805265 hasRelatedWork W2132907989 @default.
• W2014805265 hasRelatedWork W2187412430 @default.
• W2014805265 hasRelatedWork W2194088344 @default.
• W2014805265 hasRelatedWork W2780826005 @default.
• W2014805265 hasRelatedWork W4447487 @default.
• W2014805265 hasRelatedWork W71024759 @default.
• W2014805265 hasRelatedWork W2291966339 @default.
• W2014805265 isParatext "false" @default.
• W2014805265 isRetracted "false" @default.
• W2014805265 magId "2014805265" @default.
• W2014805265 workType "article" @default.